About corvus pharmaceuticals inc - CRVS
Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.
CRVS At a Glance
Corvus Pharmaceuticals, Inc.
901 Gateway Boulevard
South San Francisco, California 94080
| Phone | 1-650-900-4520 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -15,283,000.00 | |
| Sector | Health Technology | Employees | 37 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
CRVS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 9.397 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.882 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.002 |
CRVS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -413,054.054 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
CRVS Liquidity
| Current Ratio | 6.206 |
| Quick Ratio | 6.206 |
| Cash Ratio | 6.05 |
CRVS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -21.829 |
| Return on Equity | -32.596 |
| Return on Total Capital | -24.594 |
| Return on Invested Capital | -32.092 |
CRVS Capital Structure
| Total Debt to Total Equity | 1.531 |
| Total Debt to Total Capital | 1.508 |
| Total Debt to Total Assets | 1.318 |
| Long-Term Debt to Equity | 0.872 |
| Long-Term Debt to Total Capital | 0.859 |